Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate ( CING ) to $16 from $17 and keeps a Buy rating on the shares after meeting with its management to discuss Q3 results. The company is ratcheting up its CTx-1301 U.S. pre-commercialization efforts through its Indegene partnership, though the firm is adjusting its model on expectation that Cingulate may choose to raise capital during the next 6 to 12 months, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
-
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
-
Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. >","yLinkElement":"context_link","yModuleName":"content-canvas","yTrafficOrigin":"content-canvas default"}" rel="noopener noreferrer nofollow"> Try Now>>
Read More on CING:
